Liying Zhang

Liying Zhang

Auto-generated profile, based on publicly available information

Liying Zhang

Sunnybrook Health Sciences Centre, Toronto, Ohio, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2019 in Blood Advances
Verified
Journal Article
Closed access
PDF file
ECElina K. Cook
Elina K. Cook
TITerumi Izukawa
Terumi Izukawa
SYSherylan Young
Sherylan Young
GRGili Rosen
Gili Rosen
MJMina Jamali
Mina Jamali
MRMichael J. Rauh
Michael J. Rauh
Key Points: CH may be associated with broader ill health (worse performance status, increased and potentially novel comorbidities). Serum interleukin-6 is elevated in people with CH and genetic subtypes, providing a view of the human systemic inflammatory landscape of CH.

1 June 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
TBTara Behroozian
Tara Behroozian
LMLauren Milton
Lauren Milton
LZLiying Zhang
Liying Zhang
JLJulia Lou
Julia Lou
IKIrene Karam
Irene Karam
ECEdward Chow
Edward Chow

6 February 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
WOWee Loon Ong
Wee Loon Ong
PCPatrick Cheung
Patrick Cheung
HCHans Chung
Hans Chung
WCWilliam Chu
William Chu
JDJay Detsky
Jay Detsky
ALAndrew Loblaw
Andrew Loblaw

13 June 2024 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JHJohn M. Hudson
John M. Hudson
ALAndrew Loblaw
Andrew Loblaw
MMMerrylee McGuffin
Merrylee McGuffin
HCHans T. Chung
Hans T. Chung
CTChia-Lin Tseng
Chia-Lin Tseng
GMGerard Morton
Gerard Morton
High dose-rate (HDR) brachytherapy as a monotherapy is an accepted treatment for localized prostate cancer, but the optimal dose and fractionation schedule remain unknown. We report on the efficacy of a randomized Phase II trial comparing HDR monotherapy delivered as 27 Gy in 2 fractions vs. 19 Gy in 1 fraction with a median follow-up of 9 years. Enrolled patients had low or intermediate-risk disease, <60 cc prostate volume and no androgen deprivation use. Patients were randomized to 27 Gy in 2 fractions delivered one week apart vs a single fraction of 19 Gy. 170 patients were randomized: median age 65 years, median follow-up 107 months and median baseline PSA 6.35 ng/ml. NCCN risk categories comprised low (19 %), favourable (51 %), and unfavourable intermediate risk (30 %). The median PSA at 8 years was 0.08 ng/ml in the 2-fraction arm vs. 0.89 ng/ml in the single-fraction arm. The cumulative incidence of local failure at 8 years was 11.2 % in the 2-fraction arm vs. 35.9 % in the single-fraction arm (p < 0.001). The incidence of distant failure at 8 years was 3.8 % in the 2-fraction arm and 2.5 % in the single-fraction arm (p = 0.6). HDR monotherapy delivered in two fractions of 13.5 Gy demonstrated a persistent cancer control rate at 8 years and was well-tolerated. Single-fraction monotherapy yielded poor oncologic control and is not recommended. These findings contribute to the ongoing discourse on optimal HDR monotherapy strategies for low and intermediate-risk prostate cancer.

6 July 2018 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
LZLiying Zhang
Liying Zhang
YLYali Luo
Yali Luo
ZLZhiwei Lu
Zhiwei Lu
JHJinpeng He
Jinpeng He
LWLei Wang
Lei Wang
LYLiu Yongqi
Liu Yongqi
BACKGROUND:This study investigated the effect of Astragalus polysaccharides (APS) on radiation-induced bystander effects (RIBE) in human bone mesenchymal stem cells (BMSCs) induced by irradiated A549 cells. MATERIAL AND METHODS:A549 cells were irradi...

1 October 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
SCSierra Cheng
Sierra Cheng
VAVanessa Arciero
Vanessa Arciero
Hanan GoldbergHanan Goldberg
Hanan Goldberg
CTCamilla Tajzler
Camilla Tajzler
AMAileen Manganaro
Aileen Manganaro
Urban EmmeneggerUrban Emmenegger
Urban Emmenegger
Introduction: Radium-223 (Ra223) prolongs the survival and improves the quality of life of men with metastatic, castration-resistant prostate cancer (mCRPC) to bones. However, compared to other mCRPC therapies, using Ra223 comes with its unique challenges. Hence, we aimed to identify Ra223 utilization patterns under real-world conditions, as well as factors predicting treatment completion and outcome. Methods: In this retrospective chart analysis, 198 mCRPC patients were identified that had received Ra223 outside of clinical trials or access programs from January 2015 to October 2016 at four cancer centres in Ontario. The main outcomes studied were Ra223 completion rate, reasons for early treatment discontinuation, overall survival, and survival differences in patients completing Ra223 therapy versus patients receiving <6 cycles of Ra223. In addition, patient and disease characteristics were analysed to identify predictors of treatment completion and survival. Results: In this cohort of patients mostly pretreated with abiraterone and/or enzalutamide (92.4%), almost half of which had also received docetaxel (48.5%), the Ra223 completion rate was 46.5%, and the actuarial median survival was 13.3 months. The main reason for early Ra223 discontinuation was disease progression, and Ra223 non-completion was associated with poorer outcome (median survival 8.1 months [6.0–12.2] versus 18.7 months [15.3–22.3] in men completing Ra223, p<0.0001). Lymph node metastases and a high baseline prostate-specific antigen (PSA) were independent predictors of early treatment discontinuation. Multivariable Cox proportional hazards models revealed early Ra223 discontinuation, baseline anemia, high PSA, prior skeletal-related events, visceral metastases, and being referred to another centre for Ra223 therapy as predictors of worse outcome. Conclusion: Despite a lower completion rate than observed under clinical trial conditions, the real-world results achieved with Ra223 are encouraging. If prospectively validated, predictive patient and disease characteristics identified in our cohort might become instrumental to identify mCRPC patients likely to complete and to most benefit from Ra223 therapy.